NURS 306

- Epidemiologic Orientation of Health and Disease
-definition and introduction
- health and disease
- natural history of disease
- levels of prevention
- Epidemiologic Concepts
- scope
- epidemic versus endemic disease
- multiple causation of disease
- outbreak investigation


## NURS 306

- Epidemiology - the study of the distribution and determinants of of diseases and injuries in human populations
- Frequency and types of illness/injury
- Health planning
- What groups of people have illness/injury
- Factors that affect disease status
-Quantify the natural history of disease
- Evaluate new management strategies


## NURS 306

-Evaluation of new preventive and therapeutic measures

- Impacts on health outcome
- Foundation for public policy and regulatory decisions
- Health policy decision making
- Some Historical Context
$-18^{\text {th }}$ Century
- Edward Jenner - Small Pox
$-19^{\text {th }}$ Century
- John Snow - Cholera

| NURS 306 |
| :---: |
| -Evaluation of new preventive and therapeutic measures <br> - Impacts on health outcome |
| -Foundation for public policy and regulatory decisions <br> - Health policy decision making |
| - Some Historical Context - $18^{\text {th }}$ Century |
| - Edward Jenner - Small Pox -19th Century |
| - John Snow - Cholera |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

## NURS 306

- Knowledge of health and disease
- anatomy, microbiology, pathology, immunology, clinical medicine, etc.
$\qquad$
- 3 basic groups
- basic sciences
- clinical medicine
- population medicine - community medicine - preventative medicine
- public health
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$


## NURS 306

$\qquad$

- Clinical Medicine
- care of individuals
$\qquad$
- sick people present themselves for treatment $\qquad$
- Population Medicine $\qquad$
-community rather than individual patient is the focus
- need to evaluate the health of a defined
$\qquad$ community
- many who may benefit from but do not seek medical care


## NURS 306

## - An Example:

- Tuberculosis
- basis science is concerned with the tubercle bacillus
- structure, growth, resistance to antibiotics
- clinical medicine revolves around
- diagnostic testing, extent/stage of the disease, choice of therapy, adequate patient follow-up


## NURS 306

## - Population Medicine

- Tuberculosis approached as a community problem
- high occurrence in susceptible groups: HIV+, infants, alcoholics
- need to follow-up with household contacts of cases
- assurance that chemotherapy is continued for an adequate period
- costs
- burden - inpatient vs outpatient
- family support - cultural attitudes
- Systematic way of studying the patterns of disease and the patterns of medical care delivery


## NURS 306

- Health and Disease
- usually defined in terms of disease
- health is a relatively illusive concept
- WHO (1948)
- Health is a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity.


## NURS 306

## - Rates

- basic epidemiologic measure of health and disease
- relates cases or events to a defined population
- Rate=events,cases,deaths/ population for a given time period
- those in the denominator must be at risk of appearing in the numerator
- eg. 12 deaths/100,000 farm population per year from work related agricultural injuries
- Looking at just the number of events or cases can be misleading

|  | NURS 306 |  |
| :---: | :---: | :---: |
| For example: |  |  |
| Cars | Private Planes |  |
| Fatilites per year | 1000 | 50 |
| Number exposed | 100,000 | 1,000 |
| Rate of fatal injury | $\frac{1,000}{100,000}=0.01$ | 50 |
|  | $10 / 1000$ | 1,000 |
|  |  | $50 / 1000$ |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

## NURS 306

## - Natural History of Disease

$\qquad$
-development of disease

- irregular and/or evolving
$\qquad$
- label of diseased or not diseased may be arbitrary
- course of disease over time
- chronic disease may have several stages
- each disease will have its own distinct course


## NURS 306

## - Stages of Disease

- Susceptibility
- groundwork laid prior to development of disease
- Pre-symptomatic
- no signs or symptoms
- changes to the disease state have started to occur
- Clinical
- recognizable signs and symptoms of disease
- therapeutic classification of the disease


## NURS 306

## - Stages of Disease

- Disability
- post disease
- disease has run its course
- or has been successfully treated
- usually defined by functional activities that can be performed
- varies between individuals with like impairment
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$


## NURS 306

- Levels of Prevention
$\qquad$
- In general this means inhibiting the disease process before is it occurs $\qquad$
-Primary
- Health promotion $\qquad$
- provision of healthy living conditions
- health education
- Protective measures $\qquad$
-immunization
- sanitation
- occupational health standards


## NURS 306

## - Secondary

- early detection of disease
- prompt treatment
- Tertiary
- minimizing disability
- maximize individual's residual capacity
-emphasis on remaining ability versus limitations


## NURS 306

- Application of prevention and natural history - stroke
- stroke - neurological deficit lasting at least 24 hours which results from damage to the brain by altered blood supply
- effects variable
- impairment of speech and/or paralysis
- a leading cause of death in Canada


## NURS 306

- Epidemiology has contributed to the understanding of the natural history of stroke $\qquad$
-not a random event
-risk factors developed early in life linked to $\qquad$ future stroke
-several populations followed over a $\qquad$ number of years have provided information on these factors $\qquad$
-eg. Hypertension, cardiac impairment


## NURS 306

- Identification of high blood pressure $\qquad$
- led to a series of intervention trials
- reduced BP resulted in lower mortality in intervention groups
- these interventions as well as health promotion campaigns have resulted in a gradual decline in mortality due to stroke in the past 30 years


## NURS 306

- Scope of Epidemiology
- early epidemiology was largely concerned with infectious disease
- epidemiologic methods are now applied to all diseases, conditions, and health related events


## NURS 306

- Epidemic versus Endemic Disease
- Endemic - the constant presence of a disease or infectious agent within a population - prevalence of disease
- Epidemic - the occurrence in a population of an illness that is clearly in excess of normal expectancy


## NURS 306

- Epidemic
- may include any kind of disease or injury
- no general rule on the number of cases
-no specific geographic extent
- no specific time period eg.food poisoning to drug addiction
- epidemics that run over a number of years may be considered endemic

| NURS 306 |
| :--- |
| - Epidemic |
| - may include any kind of disease or injury |
| - no general rule on the number of cases |
| - no specific geographic extent |
| -no specific time period eg.food poisoning |
| to drug addiction |
| - epidemics that run over a number of years |
| may be considered endemic |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

## NURS 306

- Multiple Causation of Disease
- humans are considered the host organism
- humans interact with a variety of organisms and agents in an ecological system
- many diseases require more than one factor to be present
- Multi -factorial etiology or multiple causation
- organism is not exclusively causal
- necessary but often not sufficient
- host and environmental conditions also necessary


## NURS 306

- Host Factors
- genetic endowment
- blood type and ulcers
- specific immunity
- measles, chicken pox
- personality
- type A versus type B


## NURS 306

- Extrinsic Factors (environmental)
- biological environment
- infectious disease agents
- reservoirs of infection
- vectors that transmit disease
- plants and animals (sources of food and medication)
- social environment
- economics
- politics
- social integration
- social customs
- family


## NURS 306

- Physical environment
- heat
- light
- air
- water
- radiation
- chemical agents
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
- etc.

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$



## NURS 306

- Who
- Characteristics of the human host
- Age
- Gender
- Race
$\qquad$
- When
- Periodicity of the disease
- Seasonal
- Event related
- Where
- Not randomly distributed by geography
- Often related to disease vectors
- Hanta virus, rabies
- Related to the environment


## NURS 306

## - Objectives

- Describe measures of morbidity
- Discuss problems of measuring morbidity
- Describe measures of mortality
- Discuss problems of measuring mortality
- Describe methods of comparing mortality in different populations
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$



## HSSC 601

- Definition
- Epidemic
- any increase in incidence of a particular condition in excess of what is normally expected, also known as epizootic in animals
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

| HSSC 601 |
| :---: |
| - Definition |
| - Pandemics |
| • widespread epidemics, cover a large geographic |
| area eg.AlDS, malaria, influenza |

- Rate vs. Ration vs. Proportion
- Rate
- are those measures of disease occurrence that include time in the denominator (e.g.: incidence)
- Ratio
- a fraction in which the numerator is not necessarily a subset of the denominator
- Proportion
- a fraction in which the numerator contains a subset of the individuals contained in the denominator

HSSC 601 $\qquad$

- Measures of Morbidity $\qquad$
- Incidence per 1,000=

No. of new cases of a disease occurring in
$\qquad$
$\qquad$ the population during a specified time period X 1000
No. of persons in the population at that $\qquad$ specified time

## HSSC 601

## - Incidence

- NEW cases of disease
- Arbitrary choice of per/denominator e.g.
cases/1000, cases/10,000 etc.
- Measure of risk
- Transition from well to diseased state
- Can be sub-divided by group
- Sex, occupational status, age etc.
- Denominator
- Persons at risk of developing disease
- Time is included in the denominator
- 1 week, 1 month, 1 year for group comprising the denominator
- Cumulative incidence

Incidence density - cumulative observation for different observation periods
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

| HSSC 601 |
| :---: |
| - Incidence |
| - NEW cases of disease |
| - Arbitrary choice of per/denominator e.g. |
| cases/1000, cases/10,000 etc. |
| - Measure of risk |
| - Transition from well to diseased state |
| - Can be sub-divided by group |
| - Sex, occupational status, age etc. |
| - Denominator |
| - Persons at risk of developing disease |
| - Time is included in the denominator |
| - 1 week, 1 month, 1 year for group comprising the |
| denominator |
| - Cumulative incidence |
| - Incidence density - cumulative observation for different |
| observation periods |

$\qquad$

| HSSC 601 |
| :---: |
| - Measures of Morbidity |
| - Prevalence $=$ |
| No. of cases of a disease present in the <br> population during a specified time period |
| No. of persons in the population at that |
| specified time |$\quad 1000$

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

## HSSC 601

$\qquad$

- Prevalence $\qquad$
- Slice through the population at a point in time to count how many of the disease $\qquad$
- Does not take into account the duration of
$\qquad$
- Point prevalence
- Disease present at a point in time
- Disease present in a certain time period $\qquad$
- Not a measurement of risk
- Different durations of disease
- No clear measurement point as with incidence (new cases)


## HSSC 601

- Examples of Point and Period Prevalence Interview Question Type of Measure

Do you currently have -Point Prevalence asthma?
Have you had asthma -Period Prevalence during the last ( n )
years?
Have you ever had asthma?
-Cumulative or asthma? lifetime incidence

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

HSSC 601 $\qquad$
Factors influencing prevalence

- Increased by:
- Decreased by:
- shorter duration
- high case-fatality
- decrease in new cases
- increase in new cases
- in-migration of healthy persons

HSSC 601

- The relationship of prevalence to incidence - Prevalence= incidence * duration of disease - Example
- Tuberculosis
- Screen 1000 people in the suburbs and 1000 people in the inner city
»P Point prevalence in both is 100 cases/1000 pop.
" However:
"In the suburbs there are 4 new cases per year that live 25 years each
" In the inner city there 25 new cases per year that live 4 years
"Therefore the prevalence could be the same with dramatically different incidence


## HSSC 601

- Problems with measuring morbidity $\qquad$
- definition of who has the disease
- case finding
- available cases or
- special study
$\qquad$
$\qquad$ - hospital data
- admission policies $\qquad$
- records are for administrative purposes
- diagnostic quality/coding $\qquad$
- denominator - catchment area


## HSSC 601

## - Other problems

$\qquad$

- undercounting of population
- classification of various groups $\qquad$
- Aboriginal status
- farm worker
-denominator eligibility

HSSC 601

- Sources of Morbidity Data
- Disease registries
- Public/Private insurance plans
- Provincial hospital data
- Physician claims
- Drug plans
- Life insurance
- Hospitals and clinics
- Work records (absenteeism or employee health) $\qquad$
- Population health surveys
- Cancer, injury, general health

HSSC 601

- Possible Sources of Error in Health Surveys
- Persons may be unaware that they have a disease
- Asymptomatic or non-recognition
- Misunderstanding of the diagnosis
- Accuracy of the recall of health events
- Confusion regarding specific events
- Time frame covered by the interview
- Interviewer error
- Data transcribing
- Probing
- Incorrect posing of questions
- Selection bias
- e.g. poor response by young single males

HSSC 601

- Limitations of Hospital Data
-Selectivity of admission
- Personal characteristics
- Severity of the disease
- Associated conditions
- Admission policies
- Records not designed for research
- Incomplete, illegible, missing
- Variable diagnostic quality
- Population at risk is generally not well defined

HSSC 601

- Measures of Mortality
- crude mortality rates
- specific mortality rates: age, cause, gender, etc.
- case fatality rates
- proportionate mortality
- standardised mortality ratio (SMR)
- adjusted rates: direct, indirect
- years of potential life lost (YPLL)
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
- Why look at mortality data?
- Least expensive method of surveillance
- Provides information on changing health care needs
- Provides clues for changes in patterns of disease occurrence
- Mortality data is an appropriate indicator of
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$ disease risk only when:
- the case fatality rate is high (rabies), and
- the duration of the disease is short (pancreatic $\qquad$ cancer)


## HSSC 601

- Sources of Mortality Data
- medical examiners $\qquad$
- death certificates
- Immediate cause: rupture of myocardium $\qquad$
- due to: myocardial infarction
- due to: ischemic heart disease $\qquad$
- other significant conditions: COPD, Diabetes
- Problems
- changes in disease definition over time
- actual cause vs. other disease presence
- case and denominator definitions


## HSSC 601

- Reported Causes of Death
- A mother died in infancy
- Deceased had never been fatally sick $\qquad$
- Died suddenly, nothing serious
- Went to bed feeling well, but woke up dead $\qquad$
- Died suddenly, without the aid of a physician

| HSSC 601 |
| :---: |
| - Annual Mortality Rate |
| $\frac{\text { Total no. of deaths from all causes in } 1 \text { yr. }}{\text { No. of persons in the population at midyear }}$ |
| Usually expressed at per 1,000 |
|  |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

| HSSC 601 |
| :---: |
| - Age-specific mortality rate |
| No. of children in the population under age 10 yrs. at <br> midyear <br> the age of 10 |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

| HSSC 601 |
| :---: |
| - Cause specific rate |
| $\frac{\text { No. of deaths from lung cancer per year }}{\text { No. of persons in the population at midyear }}$ |
|  |
|  |
|  |


| HSSC 601 |
| :---: |
| - Case-fatality rates (percent) |
| No. of individuals dying during a specified period of <br> time after disease onset or diagnosis <br> No. of individuals with the specified disease <br>  <br> ${ }^{*}($ x100 $)$ |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

| HSSC 601 |
| :---: |
| - Proportionate mortality |
| $\frac{\text { No. of deaths from cardiovascular disease in '98 }}{\text { Total deaths in '98 }}$ |
|  |
|  |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

| HSSC 601 |
| :--- |
| - Years of Potential Life Lost (YPLL) |
| - All causes |
| - Injuries |
| - Cancers |
| - Suicide/Homicide |
| - Heart Disease |
| -Congenital Anomalies |
| -AIDS |
|  |

## HSSC 601

## - Adjustment of death rates

- Direct age adjustments
- Standard population is applied to two or more different populations to allow comparison
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

| - Comparison of total death rates in a population at two difforent timo poriods <br> Early Period Later Period |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |
| Populatio <br> n | No. of Deaths | Death Rate per 100,000 | Populatio <br> n | No. of Deaths | Death Rate per 100,000 |
| 900,000 | 862 | 96 | 900,000 | 1,130 | 126 |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

| Comp |  | on-spe rly P | $\begin{aligned} & \text { SC } 6 \\ & \text { od death } \end{aligned}$ | $301$ <br> tes at two La | differe ter Per | $\begin{aligned} & \text { time perin } \\ & \text { iod } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Age Group | Population | No. of Deaths | $\begin{array}{\|l\|l\|} \hline \begin{array}{l} \text { Death Rate } \\ \text { per 100,000 } \end{array} \\ \hline \end{array}$ | Population | No. of Deaths | $\begin{array}{\|l\|} \hline \text { Death Rate } \\ \text { per 100,000 } \end{array}$ |
| All ages | 900,000 | 862 | 96 | 900,000 | 1,130 | 126 |
| 30-49 | 500,000 | 60 | 12 | 300,000 | 30 | 10 |
| 50-69 | 300,000 | 396 | 132 | 400,000 | 400 | 100 |
| 70+ | 100,000 | 406 | 406 | 200,000 | 700 | 350 |


| HSSC 6O1 |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- |
| Age <br> Group Standard <br> Populatio <br> n "Early" <br> Rate per <br> 100,000 Expected <br> No. of <br> Deaths <br> Using <br> "Early" <br> Rate "Later" <br> Rate per <br> 100,000 <br> All $1,800,00$ Expected <br> No. of <br> Deaths <br> Using <br> "Later" <br> Rate   <br> $30-49$ 800,000 12 96 10 <br> $50-69$ 700,000 132 924 100 <br> $70+$ 300,000 406 1,238 350 <br> Total no. of deaths expected 2,238 1,050   |  |  |  |  |
| Age Adjusted Rates |  |  |  |  |
| "Early" $=2,238 / 1,800,000=124.3$ |  |  |  |  |
| "Later" $=1,830 / 1,800,000=101.7$ |  |  |  |  |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

## HSSC 601

## - Adjustment of death rates

$\qquad$
-Standardized mortality ratios

Observed no. of deaths per year
Expected no. of deaths per year

## HSSC 601

| Age | Est. Pop. of <br> Miners | Death Rate <br> (per <br> $100,000)-$ <br> Males <br> General | Expected <br> Deaths | Observed <br> Deaths |
| :--- | :--- | :--- | :--- | :--- |
|  | $(1)$ | Pop.(2) | $(3)=(1)^{*}(2)$ | $(4)$ |
| $20-24$ | 74,598 | 12.26 | 9.14 | 10 |
| $25-29$ | 85,077 | 16.12 | 13.71 | 20 |
| $30-34$ | 80,845 | 21.54 | 17.41 | 22 |
| $35-44$ | 148,870 | 33.96 | 50.55 | 98 |
| $45-54$ | 102,649 | 56.82 | 58.32 | 174 |
| $55-59$ | 42,494 | 75.23 | 31.96 | 112 |
| Totals |  |  | 181.09 | 436 |

$\qquad$
$\qquad$

## HSSC 601

Standardized Mortality Ratio (SMR)
= Observed Deaths/Expected Deaths
$=436 / 181.09 * 100=241$

Over 100 indicates excess in mortality

Less than 100 indicates less death than expected

## HSSC 601

- Quality of Life
$\qquad$
-Quality Adjusted Life Years
-Disability Adjusted Life Years
- Major challenge here is differences in $\qquad$ response on quality of life measures by race, education, culture, religious values $\qquad$ etc.


## NURS 306

- Assessing the Validity and Reliability of Diagnostic and Screening Tests
-Objectives
- Define Sensitivity and Specificity
- Define Predictive Value
- Discuss Reliability of Tests


## - Biologic Variation

- Tests are used to distinguish between individuals
- diagnosing disease when symptoms present
- screening of populations for early intervention - Distribution of test results
- bi or poly-modal
- unimodal
- no obvious cutoff to delineate well from healthy
- large gray area between extreme values


## - Validity

- the ability of the test to distinguish between who has the disease and who does not
- Sensitivity
-the ability of the test to identify correctly those who have the disease
- Specificity
- the ability of the test to identify correctly those who do not have the disease


$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
- Specificity

| Test <br> Results | Population |
| :--- | :--- | :--- |
| With Disease | Without Disease |

$$
\text { Specificity }=\frac{\mathrm{TN}}{\mathrm{TN}+\mathrm{FP}}
$$

## - Specificity

| Test <br> Results | With Disease | Population <br> Without Disease |  |
| :--- | :---: | :---: | :---: |
| Positive | 80 | 100 |  |
| Negative | 820 |  |  |
|  | 20 | 800 |  |
|  | 100 | 900 |  |
|  | Specificity $=\frac{800}{900}$ | $=89 \%$ |  |

## - Assessment of Tests

- must compare results with "gold standard"
- biopsy results, death etc.
- often more invasive and/or expensive
- would like all results to be true positives or true negatives
- this rarely happens
- consequences of false positives and false negatives need to be considered
- False positives
- burden on health system with further work-up
- labeling of people with disease status
- assume sick role
- may be denied insurance
- False negatives
- may not receive treatment in time - depends on nature and severity of disease
- effectiveness of available treatments
" greater effectiveness if early intervention in many cases
- For tests of continuous variables (unimodal distribution)
- Cut-points must be chosen to determine disease status
- importance of false positives - emotional and financial costs
- importance of false negatives
- serious disease may be missed at an early stage

Higher Cut-points $\rightarrow \downarrow_{\text {sensitivity }} \uparrow_{\text {specificity }}$
Lower Cut-points $\rightarrow$ sensitivity $\downarrow$ specificity Lower Cut-point $\rightarrow$ Tsenitivity $\downarrow$ specificity
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

- Two stage screening
- less expensive, less invasive, or less uncomfortable test is carried out first
- positives are then given a more expensive or invasive test
- often with better sensitivity and/or specificity
$-\uparrow$ net sensitivity and/or $\uparrow$ net specificity


## - Predictive Value of a Test

- Positive Predictive Value
- what proportion of patients who test positive actually have the disease
- Negative Predictive Value
- what proportion of patients who test negative actually do not have the disease
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$


$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$


## - Negative Predictive Value

$\qquad$
Test
Population

|  | Results | With Disease |
| :--- | :--- | :--- |

Negative Predictive Value $=\frac{\mathrm{TN}}{\mathrm{FN}+\mathrm{TN}}$

| - Negative Predictive Value |  |  |  |
| :---: | :---: | :---: | :---: |
| Test Results | Population |  | 180 |
|  | With Diseas | hout Diseas |  |
| Positive | 80 | 100 |  |
| Negative | 20 | 800 | 820 |
|  | 100 | 900 |  |
|  | Negative Predictive Value = |  | 8\% |

## - Population Prevalence and Predictive Value

- higher prevalence of disease generally leads to greater positive predictive value of a test
- screening the general population for a rare disease can be wasteful
- high risk subsets can be identified
- age, genetic background, gender
- general practice vs. tertiary specialist
- 1\% Population Prevalence

| Results | Por |  | 594 |
| :---: | :---: | :---: | :---: |
|  | With Disease | Without Disease |  |
| Positive | 99 | 495 |  |
| Negative | 1 | 9405 | 9406 |
|  | 100 | 9900 |  |
|  | Positive Predictive Value $=$ | Value $=\quad 99$ | = $17 \%$ |
|  |  | 594 |  |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

## - 5\% Population Prevalence

| - 5\% Population Prevalence |  |  |  |
| :---: | :---: | :---: | :---: |
| Test <br> Results | Population |  | 970 |
|  | With Disease | Without Disease |  |
| Positive | 495 | 495 |  |
| Negative | 5 | 9025 | 9030 |
|  | 500 | 9500 |  |
|  | Positive Predictive Value $=$ | - 495 | 1\% |
|  |  | 970 |  |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

- Specificity and Predictive Value
$-\uparrow$ specificity $=\uparrow$ positive predictive value
- most individuals are not diseased
- therefore changes to the right side of the $2 x 2$ table will have a greater effect on test diagnostics


## - Reliability of Tests

- Are results the same if the test is repeated?
- If not, test is pretty useless
-Factors that effect variation between tests
- Intra-subject
- variation within individuals
- Inter-observer
- variation between those reading the tests
- Intra-subject Variation
-time
-setting
- fatigue
-motivation
- etc.
- Inter-observer Variation
-training
- experience
-time spent doing test
-etc.
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
- Measures of Reliability between Observers/Raters
- Overall percent agreement
- for cells where raters agree
- may over estimate because there will be much agreement from large numbers of negative tests
- for only cells where raters agree on positive tests
- neither of these factor in chance
-Kappa Statistic
- factors in chance agreement
- =(percent observed agreement-percent agreement by chance alone)/(100\%-percent agreement by chance alone)
Percent Agreement $=[(a+d) /(a+b+c+d)]^{*} 100$

$$
=[(41+27) /(41+3+4+27)] * 100
$$

$$
=(68 / 75) * 100
$$

$$
=90.7 \%
$$

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

| Pathologist B | PathologistA |  | 44 |
| :---: | :---: | :---: | :---: |
|  | sitive | gative |  |
| Positive | 41(26.4) | 3(17.6) |  |
| Negative | 4(18.6) | 27(12.4) |  |
| 45 |  | 30 | 315 |
| $\begin{aligned} & \text { Percent Agreement by Chance } \\ & =[(26.4+12.4) / 75] * 100 \\ & =51.7 \% \end{aligned}$ |  |  |  |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

## Kappa Statistic

$=($ percent observed agreement-percent agreement by chance alone) $/(100 \%$-percent agreement by chance alone)

## Kappa Statistic

$=(90.1 \%-51.7 \%) /(100 \%-51.7 \%)$
$=39 \% / 48.3$
$=.81$

## Interpretation

.75 or greater - excellent agreement .40 to .75 - intermediate to good agreement less than .40 - poor agreement


## NURS 306

- Prognosis
- natural history of disease
- define prognosis
- lead time bias
- life tables


## - Natural History of Disease

$\qquad$

- needs to be quantified
- severity needs to be described $\qquad$
- establish priorities
" clinical services
" public health programs $\qquad$
- patients need to know
- baseline for new treatments $\qquad$
- expected outcomes vs. new treatment
- compared effectiveness of different treatments $\qquad$
$\qquad$
$\qquad$


## - Natural History of Disease



| - Five Year Survival |
| :--- |
| - frequently employed in clinical medicine |
| - percent of patients alive after 5 years of |
| diagnosis or treatment |
| - derived from cancer statistics |
| - most deaths occur during this period |
| - lead time bias as a result of screening | | - Five Year Survival |
| :--- |
| - frequently employed in clinical medicine |
| - percent of patients alive after 5 years of |
| diagnosis or treatment |
| - derived from cancer statistics |
| - most deaths occur during this period |
| - lead time bias as a result of screening | | - Five Year Survival |
| :--- |
| - frequently employed in clinical medicine |
| - percent of patients alive after 5 years of |
| diagnosis or treatment |
| - derived from cancer statistics |
| - most deaths occur during this period |
| - lead time bias as a result of screening | | - Five Year Survival |
| :--- |
| - frequently employed in clinical medicine |
| - percent of patients alive after 5 years of |
| diagnosis or treatment |
| - derived from cancer statistics |
| - most deaths occur during this period |
| - lead time bias as a result of screening | | - Five Year Survival |
| :--- |
| - frequently employed in clinical medicine |
| - percent of patients alive after 5 years of |
| diagnosis or treatment |
| - derived from cancer statistics |
| - most deaths occur during this period |
| - lead time bias as a result of screening | | - Five Year Survival |
| :--- |
| - frequently employed in clinical medicine |
| - percent of patients alive after 5 years of |
| diagnosis or treatment |
| - derived from cancer statistics |
| - most deaths occur during this period |
| - lead time bias as a result of screening | | - Five Year Survival |
| :--- |
| - frequently employed in clinical medicine |
| - percent of patients alive after 5 years of |
| diagnosis or treatment |
| - derived from cancer statistics |
| - most deaths occur during this period |
| - lead time bias as a result of screening |

## - Questions

- At what point do we begin to quantify survival time?
- Biologic onset
- not usually known or measurable
- symptoms?
" Somewhat subjective
- Usually use diagnosis as start point
- can differ as individuals seek care differently
- people who die prior to diagnosis aren't counted


## - Case-fatality Rate

- Given that a person has the disease, what is the likelihood of death
- no explicit statement of time
- used for acute disease of short duration that results in death shortly after diagnosis
- not good for chronic disease


No. of people who have the disease
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

- Lead Time Bias

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
- Lead Time Bias $\qquad$
-extra time in the diseased state
- no extra life
- extra medical care, but no better outcome
-important in the evaluation of screening programs
- determine if screening is actually beneficial
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$


## - Observed Survival

-5 year survival rate
-commonly used in cancer studies

- measure of successful treatment to survive 5 years
-calculate the probability of survival at 5 years for a given disease and/or treatment
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

$$
8 / 84=.095(9.5 \%)
$$

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$


$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

$\qquad$

| No. Alive at End of Year |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year of Treatment | No. of Patients Treated | $1^{\text {P }}$ Year | $2^{\text {na }}$ Year | $3^{\text {rad }}$ Year | $4^{\text {In }}$ Year | $5^{\text {III }}$ Year |
| 1990 | 84 | 44 | 21 | 13 | 10 | 8 |
| 1991 | 62 | 31 | 14 | 10 | 6 |  |
| 1992 | 93 | 50 |  | 13 |  |  |
| 1993 | 60 | 29 | 16 |  |  |  |
| 1994 | 76 | 43 |  | Surviving | 4th Year $=$ | (36-13) $=.70$ |
| Total |  |  |  | 36 | 16 |  |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

| Year of Treatment | No. of <br> Patients <br> Treated | No. Alive at End of Year |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $1^{\text {² }}$ Year | $2^{\text {nd }}$ Year | $3^{\text {ra }}$ Year | $4^{117}$ Year | $5^{\text {III }}$ Year |
| 1990 | 84 | 44 | 21 | 13 | 10 | 8 |
| 1991 | 62 | 31 |  | 10 | 6 |  |
| 1992 | 93 | 50 | 20 | 13 |  |  |
| 1993 | 60 | 29 | 16 |  |  |  |
| 1994 | 76 | 43 |  | Surviving th | 5th Year = | 16-6) $=.80$ |
| Total |  |  |  |  | 16 | 8 |

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

Probability of Survival for Each Year of the Study

- $P 1=$ Probability of surviving the first year $=197 / 375=0.52=52 \%$
- $P 2=$ Probability of surviving the second year given survival to the end of the first year $=71 /(197-43)=0.46=46 \%$
- $\mathrm{P} 3=$ Probability of surviving the third year given survival to the end of the second year $=36 /(71-16)=0.65=65 \%$
- $\mathrm{P} 4=$ Probability of surviving the fourth year given survival to the end of the third year $=16 /(36-13)=0.70=70 \%$
- P5 = Probability of surviving the fifth year given survival to the end of the fourth year $=8 /(16-6)=0.80=80 \%$
- What is the probability of surviving 5 years after beginning treatment?
- = P1*P2*P3*P4*P5
- $=.52^{\star} .46^{\star} .65^{\star} .70^{\star} .80$
- =. 088 or $8.8 \%$


## - Assumptions

- no change in the effectiveness of treatment during the study period
- over many years this is likely not valid
- treatments improve over time
- persons who are lost to follow-up have the same experience of those followed
- die and not traced
- seek care elsewhere
- move
- get better


## - Survival Curves

- illustrate different survival experiences
- between populations
- between treatment groups


## - Other Measures

- Median survival time
- length of time half the population survives
- less affected by extreme values than mean value - only have to track the deaths of half the group rather than all survival times
-Relative Survival Rate
- comparison of observed rate to relative rate if disease were absent
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$


## - Generalizability

-depends on the population in the study

- primary vs. tertiary care
- community vs. hospital population
- generalist vs. specialist
- clinic vs. population based
- examine selection criteria for patients included in the study and compare that to your population


## NURS 306 - Randomized Trials

- Objective in public health and clinical
$\qquad$
$\qquad$ practice is to modify the natural history of disease
- selection of best possible treatment or intervention
- randomized trials are the gold standard for establishing the effectiveness of new therapies and interventions


## - Basic Design of Randomized Trial



- Ambroise Paré - surgeon
- 1537 - unplanned trial
- Treatment of war wounds by cauterization with oil
- Ran out of oil for numerous injury
- Used a mix of egg yolks, oil of roses, and turpentine " Improved patient outcome
- James Lind - physician
- 1747 - planned trial
- Treatment of scurvy
- 12 patients
" 2 given cider, 2 given elixir vitriol, 2 given vinegar, 2 given sea water, 2 given nutmeg, 2 given lemons and oranges
- Uses of randomized trials $\qquad$
- evaluation of new drugs
- new technology
- community trials (health promotion)
- evaluation of screening programs
-delivery of health services


## - Selection of Subjects

- criteria must be pre-determined
- precise definition of who comprises the study population
- no subjective decision making by the investigator for who is in or out of the study
- procedures for subject selection needs to be reproducible by others
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
- Alternatives to Randomization
- no comparison group
- problems with inferring causal relationship
- patients may get better naturally
- cannot clearly attribute improvement to the treatment
- historical controls
- records of patients treated prior to intervention - data may be of poor quality
- necessary outcomes have not been measured
- concomitant changes over time
- healthier lifestyles
- other therapies may be developed
- may work well for fatal diseases


## - Non-equivalent Comparison Groups

- may not be of similar composition as treatment group
- systematic bias may occur in the selection of controls
- clinicians may mess with who is getting the treatment
- Predictability of patient allocation
- Randomization
- best approach to study design
- random chance of receiving or not receiving the treatment under investigation
- random numbers table
- computer generation
- coin flipping
- often patients are group assigned a priori - clinicians may have ethical issues with with-holding treatment
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
- What Does Randomization Achieve
- no subjective bias of investigators
- overt or covert
- hope that groups will be comparable on various characteristics
- variables we can measure
- unknown/non-measurable variables that impact treatment
- genetics
- immune status
- other stuff we simply don't know about
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$


Planned Crossover Design


## - Cross-over trial

- Patient serves as their own control
- Smaller sample needed
- Issues
- Carryover/washout
- Order of the therapies may elicit differential response from patients
- Enthusiasm may diminish over time


## - Blinding

- Subjects do not know the treatment they are getting
- not always possible
- use of placebo
-Double blinding
- investigators/clinicians do not know treatment group
- if not possible outcomes should be assessed by someone who does not know treatment status
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

| - Blinding |
| :--- |
| - Subjects do not know the treatment they |
| are getting |
| • not always possible |
| - use of placebo |
| - Double blinding |
| • investigators/linicians do not know treatment |
| group |
| i ino tossible outcomes should be assessed |
| by someone who does not know treatment |
| status |

## - Non-Compliance

- refuse to comply with treatment
- drop-outs
- poor compliance
- contamination
- persons who get the treatment in the control group
- other medications, desire for better outcomes - to measure effectiveness, it is important to test treatment among those who comply and those who do not - different health outcomes
- efficacy vs. effectiveness


## - Generalizability of Results

$\qquad$

- External validity
- does the study population reflect the reference $\qquad$ population
- Internal validity
- randomization worked
- few issues with non-compliance and contamination
- Cohort Studies
- Case-Control Studies
- Cross-Sectional Studies
- Estimating Risk
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$ contamination
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\square$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
- Cohort Studies
- also called prospective studies
- selection of a group of exposed and unexposed persons
- persons using and not using a needle exchange program
- persons exposed and not exposed to exercise at work
- persons exposed to mine coal dust and workers who are not
- if there is an association between the exposure and the disease we would expect more disease in the exposed group (higher incidence)
- Basic design of a cohort study

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$


## - Design (using a $2 \times 2$ table)


$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

- For Example: Smoking and CHD

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$


## - Comparing Cohort Studies With

$\qquad$ Randomized Trials
-both studies compare exposed and $\qquad$ unexposed

- cannot used randomized trials to measure $\qquad$ effects of exposure in all situations
- harmful substances $\qquad$
- cohort studies are used in many studies of toxic agents $\qquad$
- unclear in cohort studies whether it is the exposure or what led persons to be exposed that has caused the association with disease

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$


## - Selection of Study Populations

-Select groups based on exposure status

- e.g. occupational groups

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
- Selection of Study Populations $\qquad$
- Defined Population

$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

```
- Types of Cohort Studies
    - prospective or longitudinal
    - groups/population are followed forward through
        time
            - expensive
            - may take many years until outcome of interest is
            reached
            - subjects outlive the investigator
- retrospective or historical
    - use data from the past to shorten length of
        follow-up
            - outcome is determined as study is started
            - exposure is measured through past records
            - often used with military personnel
            - school populations
```


## - Potential Problems with Cohort Studies

- assessment of outcome
- should be blinded if possible
- quality of information may differ between exposed and unexposed persons $\qquad$
- losses to follow-up
- people move, die, withdraw from study $\qquad$
-non-response
- systematic bias in who participates in the study $\qquad$ - analytic bias
- strong feelings about study hypotheses may $\qquad$ introduce bias in the data analysis


## - Indications that a Cohort Study is

 Appropriate- prior evidence suggests that the exposure is related to the disease
- short time between exposure and disease $\qquad$ - reasonably frequent outcome of interest


## - Case Control Study

-design


$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$

- For Example: Smoking and CHD $\qquad$
$\qquad$

|  | CHD | Controls |
| :--- | ---: | ---: |
| Smokes | 112 | 176 |
| Non-Smoker | 88 | 224 |
| Total | 200 | 400 |
| \% Smoking | $56 \%$ | $44 \%$ |

## - Case-Control Studies

- begins with people with disease
- compares diseased persons (cases) to non-diseased persons (controls)
- Selection of Cases
- many sources
- hospital records
- generalizability is an issue
- characteristics of the hospital may affect risk factors
- physician offices
- disease registries
- incident cases
- harder to accumulate but are likely more valid
- prevalent cases
- factors may be related more to survival with the disease than the development of the disease
- cases who have died before diagnosis are not included


## - Selection of Cases

$\qquad$

- challenging problem
- selection of controls can affect the study results
- may lead to incorrect conclusions
$\qquad$
-reference population for cases may be difficult to define
- careful study design is necessary to eliminate any systematic selection of controls that will influence study results


## - Non-hospitalized controls

- neighborhood controls
- many persons no longer will answer their doors - random digit dialing
- can be used only where most people have phones
- if you are using a specific selection criteria, it may be costly and time consuming
- best friend controls
- similar to cases in socio-demographic characteristics and age
- sibling controls - genetic similarity
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
$\qquad$
- $\qquad$


## - Hospitalized Persons as Controls

- captive population who can easily be identified
- are usually not representative of general population
- referral patterns to a hospital may differ depending on clinical specialties
- selection of controls by diagnosis can be difficult


## - Matching of Cases and Controls

$\qquad$

- removes the effect of potentially confounding variables $\qquad$
- eg. Age, gender, race, socioeconomic status, etc.
- Group Matching
- same proportion of variable is apparent in the controls as with cases
- eg. $25 \%$ female cases - you would select a control group that had $25 \%$ females
- Individual Matching
- for each case, a control is selected that is like on one or more characteristics.


## - Matching

- the more characteristics that are chosen to match on the more difficult it will be to find an appropriate control
- you don't want to match on any factor that you want to study.
- This eliminates your ability to analyze the data as the proportions of the factor are the same in both the cases and controls
- control selection can result in unplanned matching - eg. Best friend controls


## - Problems of Recall

-Limitations of Recall

- Individuals may not have the information needed
- persons vary in their ability to recall information from their past
- if no systematic difference exists between cases and controls regarding limitation of recall, there is no bias
- Recall Bias
- cases and controls may differ on how they remember events - differential recall
- cases may strive to remember events that controls have totally forgotten about


## - Cross-Sectional Studies

$\qquad$

- both disease and exposure are measured simultaneously $\qquad$
- usually surveys
- cases are prevalent cases $\qquad$
- associations may be with survival rather than development of disease
-temporal relationship is not defined $\qquad$ between exposure and disease
- can provide suggestive information about a $\qquad$ factor and disease


## - Randomized Trials



$\qquad$
$\qquad$
$\qquad$

$\qquad$

